<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="int-interactant" /><meta name="keywords" content="" /><title>Simvastatin: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="41001i605.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="41001i605.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=41001i605.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="41001.htm">Appendix 1 Interactions</a> &gt; <a href="53178.htm">List of drug interactions</a> &gt; <a href="41001i590.htm">Lipid-regulating Drugs</a> &gt; <a href="41001i600.htm">Statins</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="41001i604.htm" title="Previous: Pravastatin">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="41001i606.htm" title="Next: Nicotinic Acid">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_41001i605">Simvastatin</h1><div id="pC" class="jN"><p class="int-specific-drug-name"><b>Simvastatin</b>
          has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody><tr><td><a href="41001i1124.htm">Alitretinoin</a></td><td>plasma concentration of  simvastatin reduced by alitretinoin </td><td></td></tr><tr><td><a href="41001i118.htm" name="_118">Amiodarone</a></td><td class="cBV"><b>increased risk of myopathy when  simvastatin given with amiodarone </b></td><td>Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</td></tr><tr><td><a href="41001i470.htm" name="_470">Amlodipine</a></td><td>possible increased risk of myopathy when  simvastatin given with amlodipine </td><td></td></tr><tr><td><a href="41001i1005.htm">Atazanavir</a></td><td class="cBV"><b>increased risk of myopathy when  simvastatin given with atazanavir (avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i943.htm">Bosentan</a></td><td>plasma concentration of  simvastatin reduced by bosentan </td><td></td></tr><tr><td><a href="41001i277.htm">Carbamazepine</a></td><td class="cBV"><b>plasma concentration of  simvastatin reduced by carbamazepine—consider increasing dose of simvastatin</b></td><td></td></tr><tr><td><a href="41001i168.htm">Clarithromycin</a></td><td class="cBV"><b>increased risk of myopathy when  simvastatin given with clarithromycin (avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i220.htm" name="_220">Coumarins</a></td><td> simvastatin enhances anticoagulant effect of coumarins </td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i579.htm">Danazol</a></td><td class="cBV"><b>possible increased risk of myopathy when  simvastatin given with danazol </b></td><td></td></tr><tr><td><a href="41001i1077.htm">Dasatinib</a></td><td>plasma concentration of  simvastatin possibly increased by dasatinib </td><td></td></tr><tr><td><a href="41001i468.htm" name="_468">Diltiazem</a></td><td>plasma concentration of  simvastatin increased by diltiazem—possible increased risk of myopathy</td><td></td></tr><tr><td><a href="41001i1176.htm" name="_1176">Dronedarone</a></td><td class="cBV"><b>increased risk of myopathy when  simvastatin given with dronedarone </b></td><td></td></tr><tr><td><a href="41001i874.htm">Efavirenz</a></td><td>plasma concentration of  simvastatin reduced by efavirenz </td><td></td></tr><tr><td><a href="41001i169.htm" name="_169">Erythromycin</a></td><td class="cBV"><b>increased risk of myopathy when  simvastatin given with erythromycin (avoid concomitant use)</b></td><td>Interactions do not apply to small amounts of erythromycin used topically</td></tr><tr><td><a href="41001i1153.htm">Eslicarbazepine</a></td><td>plasma concentration of  simvastatin reduced by eslicarbazepine—consider increasing dose of simvastatin</td><td></td></tr><tr><td><a href="41001i301.htm">Fluconazole</a></td><td class="cBV"><b>possible increased risk of myopathy when  simvastatin given with fluconazole—avoid concomitant use</b></td><td>In general, fluconazole interactions relate to multiple-dose treatment</td></tr><tr><td><a href="41001i1019.htm">Fosamprenavir</a></td><td class="cBV"><b>possible increased risk of myopathy when  simvastatin given with fosamprenavir—avoid concomitant use</b></td><td>Fosamprenavir is a prodrug of amprenavir</td></tr><tr><td><a href="41001i829.htm">Grapefruit Juice</a></td><td class="cBV"><b>plasma concentration of  simvastatin increased by grapefruit juice—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i933.htm">Imatinib</a></td><td>plasma concentration of  simvastatin increased by imatinib </td><td></td></tr><tr><td><a href="41001i398.htm" name="_398">Indinavir</a></td><td class="cBV"><b>increased risk of myopathy when  simvastatin given with indinavir (avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i302.htm" name="_302">Itraconazole</a></td><td class="cBV"><b>increased risk of myopathy when  simvastatin given with itraconazole (avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i298.htm" name="_298">Ketoconazole</a></td><td class="cBV"><b>increased risk of myopathy when  simvastatin given with ketoconazole (avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i922.htm">Lopinavir</a></td><td class="cBV"><b>possible increased risk of myopathy when  simvastatin given with lopinavir—avoid concomitant use</b></td><td>In combination with ritonavir as <i>Kaletra</i>® (ritonavir is present to inhibit lopinavir metabolism and increase plasma-lopinavir concentration)—see also Ritonavir</td></tr><tr><td><a href="41001i299.htm" name="_299">Miconazole</a></td><td class="cBV"><b>possible increased risk of myopathy when  simvastatin given with miconazole—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i842.htm" name="_842">Nelfinavir</a></td><td class="cBV"><b>increased risk of myopathy when  simvastatin given with nelfinavir (avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i1060.htm" name="_1060">Posaconazole</a></td><td class="cBV"><b>increased risk of myopathy when  simvastatin given with posaconazole (avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i1147.htm">Ranolazine</a></td><td>plasma concentration of  simvastatin increased by ranolazine (consider reducing dose of simvastatin)</td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td>plasma concentration of  simvastatin possibly reduced by rifampicin </td><td></td></tr><tr><td><a href="41001i400.htm" name="_400">Ritonavir</a></td><td class="cBV"><b>increased risk of myopathy when  simvastatin given with ritonavir (avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i791.htm" name="_791">Saquinavir</a></td><td class="cBV"><b>increased risk of myopathy when  simvastatin given with saquinavir (avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i905.htm">St John's Wort</a></td><td>plasma concentration of  simvastatin reduced by St John's wort </td><td></td></tr><tr><td><a href="41001i1216.htm" name="_1216">Telaprevir</a></td><td class="cBV"><b>avoidance of  simvastatin advised by manufacturer of telaprevir </b></td><td></td></tr><tr><td><a href="41001i946.htm" name="_946">Telithromycin</a></td><td class="cBV"><b>increased risk of myopathy when  simvastatin given with telithromycin (avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i1203.htm">Ticagrelor</a></td><td class="cBV"><b>plasma concentration of  simvastatin increased by ticagrelor (increased risk of toxicity)</b></td><td></td></tr><tr><td><a href="41001i1055.htm">Tipranavir</a></td><td class="cBV"><b>plasma concentration of  simvastatin possibly increased by tipranavir—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i467.htm" name="_467">Verapamil</a></td><td class="cBV"><b>increased risk of myopathy when  simvastatin given with verapamil </b></td><td></td></tr><tr><td><a href="41001i948.htm" name="_948">Voriconazole</a></td><td>possible increased risk of myopathy when  simvastatin given with voriconazole </td><td></td></tr></tbody></table><p>Simvastatin belongs to <b>Statins</b>
          and will have the following interactions:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>







<tr><td><a href="41001i499.htm">Ciclosporin</a></td><td class="cBV"><b>increased risk of myopathy when  statins given with ciclosporin </b></td><td></td></tr><tr><td><a href="41001i483.htm">Colchicine</a></td><td class="cBV"><b>possible increased risk of myopathy when  statins given with colchicine </b></td><td></td></tr><tr><td><a href="41001i1061.htm">Daptomycin</a></td><td class="cBV"><b>increased risk of myopathy when  statins given with daptomycin (preferably avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i594.htm">Fibrates</a></td><td class="cBV"><b>increased risk of myopathy when  statins given with fibrates </b></td><td></td></tr><tr><td><a href="41001i163.htm">Fusidic Acid</a></td><td class="cBV"><b>risk of myopathy and rhabdomyolysis when  statins given with fusidic acid—avoid concomitant use and for 7 days after last fusidic acid dose</b></td><td></td></tr><tr><td><a href="41001i599.htm">Gemfibrozil</a></td><td class="cBV"><b>increased risk of myopathy when  statins given with gemfibrozil (preferably avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i606.htm">Nicotinic Acid</a></td><td class="cBV"><b>increased risk of myopathy when  statins given with nicotinic acid (applies to lipid regulating doses of nicotinic acid)</b></td><td>Interactions apply to lipid-regulating doses of nicotinic acid</td></tr></tbody></table><p>Simvastatin belongs to <b>Lipid-regulating Drugs</b>
          but <b>Lipid-regulating Drugs</b>
          has no interactions information.
        </p></div><?highlighter on?><?highlighter off?><div id="pE">◄ <a accesskey="[" href="41001i604.htm">Previous: Pravastatin</a> | <a class="top" href="41001i605.htm#">Top</a> | <a accesskey="]" href="41001i606.htm">Next: Nicotinic Acid</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>